CDC Updates Hepatitis B Vaccine Recommendations for Infants: Shared Decision-Making Advised

A significant shift in hepatitis B vaccination recommendations emerged on December 5, 2025, as the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted 8 to 3 to recommend a more individualized approach to infant vaccination. The committee’s decision centers on allowing parents to make informed choices, in consultation with their healthcare providers, regarding the timing of the hepatitis B vaccine, including whether to administer the birth dose.

A Move Towards Shared Decision-Making

The ACIP recommendation introduces “individual-based decision-making,” also known as shared clinical decision-making. This means parents and doctors should weigh the benefits and risks of the vaccine, alongside the potential infection risks facing the child. Factors such as a household member with hepatitis B or frequent contact with individuals from regions where the virus is prevalent should be considered.

Did You Know? A 2019 study indicated that 57.9% of estimated births to women testing positive for the hepatitis B surface antigen in the U.S. were attributable to women born outside the country, primarily from areas with high rates of the virus.

Evaluating Ongoing Protection

The ACIP also recommended that healthcare providers and parents discuss testing antibody levels to the hepatitis B surface antigen when evaluating the need for subsequent vaccine doses. This serological testing will help determine if a child has adequate protection against the virus.

Financial Implications and Background

These recommendations are designed to maintain consistent coverage across various payment programs, including the Vaccines for Children Program, the Children’s Health Insurance Program, Medicaid, and Medicare, as well as private insurance plans. Prior to this vote, on September 19, 2025, the ACIP had already recommended universal hepatitis B testing for all pregnant women, a test covered by all insurance programs.

Expert Insight: The shift towards individual-based decision-making reflects a growing emphasis on patient autonomy and a nuanced understanding of risk factors. This approach acknowledges that a one-size-fits-all strategy may not be optimal for all infants, particularly given the declining prevalence of hepatitis B in the United States.

The ACIP’s deliberations were informed by presentations on the disease burden, vaccine safety, and immunization policies in other nations, as well as briefings from vaccine manufacturers. A presentation by Cynthia Nevison, Ph.D., highlighted that the contribution of the universal birth dose to the decline in acute hepatitis B cases is likely small, with significant reductions also attributed to improved blood screening, dialysis practices, and needle exchange programs.

U.S. Practices Compared

Vicky Pebsworth, Ph.D., RN, presented data showing that the United States’ universal birth dose recommendation is an outlier among developed countries with low hepatitis B prevalence. Deputy Secretary of Health and Human Services and CDC Acting Director Jim O’Neill stated, “The American people have benefited from the committee’s well-informed, rigorous discussion about the appropriateness of a vaccination in the first few hours of life.”

The ACIP’s recommendations will become part of the official CDC immunization schedule once adopted by the CDC director.

Frequently Asked Questions

What does “individual-based decision-making” mean?

Individual-based decision-making, or shared clinical decision-making, means parents and healthcare providers should consider vaccine benefits, risks, and infection risks when deciding when or if a child will begin the hepatitis B vaccine series.

What is the most significant risk factor for a newborn contracting hepatitis B?

According to a study presented to the ACIP, the most significant risk to newborns for being infected with the hepatitis B virus is having a mother who tests positive for the hepatitis B surface antigen.

What happens after the ACIP makes a recommendation?

A recommendation from the ACIP becomes part of the CDC immunization schedule once it is adopted by the CDC director.

How might these changes impact conversations between parents and pediatricians regarding infant vaccinations?